Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cashburn lol, read today's RNS again
lol nice deramping.
Just read the last accounts and was surprised to see how high the cashburn is. The company burn through £27.63 million in six months and said funding will be required in the second quarter of 2020. It should also be noted that Invesco holds 98million shares and has been selling down its position recently.
This is from the accounts:
"Under the current business plan and detailed cash flow forecasts, with ongoing R&D efforts focused on our rare disease products, setrusumab and alvelestat, we expect that our current on-hand cash resources will extend to the end of Q2 2020. Therefore, the Group requires additional external funding within the next 12 months to be able to continue as a going concern. Principally, this funding will be required to complete our current trials, fund our ongoing administrative costs and other general working capital and contractual financing requirements and to commence our pivotal paediatric study and the manufacturing scale up activities for setrusumab as we progress with our development plans for that program."
Reds are buys at 42.2
Additionally, Mereo will be eligible to receive up to $300 million in future clinical, regulatory and commercial milestones, tiered royalties ranging from the mid-single-digit to sub-teen percentages on global annual net sales of navicixizumab, as well as a negotiated percentage of sublicensing revenues from certain sublicensees.
A few large delayed buys coming through at today's high
Looks like the MMs are about to let it go now
MREO / Mereo BioPharma Group plc 6-K - Current Report of Foreign Issuer - 6-K
12m sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
MREO
"The 2 analysts offering 12 month price targets for Mereo BioPharma Group PLC have a median target of 670.00, with a high estimate of 690.00 and a low estimate of 650.00. The median estimate represents a 1,930.30% increase from the last price of 33.00."https://markets.ft.com/data/equities/tearsheet/forecasts?s=MPH:LSE
https://invst.ly/phd41 look at the volume
People still think there is some way to go today??
When this seller or sellers are clear it will re-rate
stag there has been plenty of volume here
They might not be selling today. Who knows. T
You mean the guy that provided you an amazing entry, highlighted the share to investors and effectively done his research for us for free! That guy?
Yes there must be selling in the background
This should be flying on that news Schroders still off loading maybe
This stock is absolutely incredible, with this RNS the price is still struggling to pass 40-f**ing pence! GL
Dont forget mr woodfords legacy any rise schroders will offload
Hopefully 90p this afternoon. Only about 35% free float. Shares will dry up. Wonder if us traders buy UK stock for this.
Looking at shares register. Novartis have 16%.
RNS only 1.5 hrs old, more to come
Other pharmas have been bagging on news like that. Maybe we take off after lunch.
I'm also in on that pretty incredible RNS.
GLA